What is the purpose of this trial?
This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.
Yale Cancer Center
Dates: 04/03/2017 - 12/30/2018
Last Updated: 05/12/2017
Study HIC#: 1608018260